Vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure
about
Blood pressure-lowering efficacy of loop diuretics for primary hypertensionBlood pressure lowering efficacy of loop diuretics for primary hypertensionUrine Aquaporin-2: A Promising Marker of Response to the Arginine Vasopressin Type-2 Antagonist, Tolvaptan in Patients with Congestive Heart FailureDiagnosis and management of hyponatremia in cancer patientsTolvaptan: the evidence for its therapeutic value in acute heart failure syndromeRenal and anti-aldosterone actions of vasopressin-2 receptor antagonism and B-type natriuretic peptide in experimental heart failure.The cardiorenal syndrome: making the connection.Long-term effects and prognosis in acute heart failure treated with tolvaptan: the AVCMA trialAcute heart failure volume control multicenter randomized (AVCMA) trial: comparison of tolvaptan and carperitideClinical benefit of tolvaptan in patients with acute decompensated heart failure and chronic kidney disease.Tolvaptan, hyponatremia, and heart failure.Renal dysfunction in acute heart failure.Echocardiographic characteristics of patients with acute heart failure requiring tolvaptan: a retrospective studyThe effect of tolvaptan on renal excretion of electrolytes and urea nitrogen in patients undergoing coronary artery bypass surgery.Use of tolvaptan vs. furosemide in older patients with heart failure : Meta-analysis of randomized controlled trials.Tolvaptan: a selective vasopressin type 2 receptor antagonist in congestive heart failure.V2 receptor antagonism with tolvaptan in heart failure.Role of tolvaptan in acute decompensated heart failure.Dual Impact of Tolvaptan on Intracellular and Extracellular Water in Chronic Kidney Disease Patients with Fluid Retention.The effects of tolvaptan on patients with severe chronic kidney disease complicated by congestive heart failure.Predictive factors for responders to tolvaptan in fluid management after cardiovascular surgery.Tolvaptan: a new tool for the effective treatment of hyponatremia in psychotic disorders.Hyponatremia in heart failure: revisiting pathophysiology and therapeutic strategies.Vasopressin-receptor antagonists.Emerging therapies for heart failure: renal mechanisms and effects.Targeting hyponatremia and hemodynamics in acute decompensated heart failure: is there a role for vasopressin antagonists?Tolvaptan for the treatment of heart failure: a review of the literature.Tolvaptan for heart failure patients with volume overload.Clinical utility of tolvaptan in the management of hyponatremia in heart failure patients.Tolvaptan for the treatment of hyponatremia secondary to the syndrome of inappropriate antidiuretic hormone secretion.Hyponatremia, heart failure, and the role of tolvaptan.Vasopressin receptor antagonists: from pivotal trials to current practice.Renal dysfunction in acute congestive heart failure: a common problem for cardiologists and nephrologists.Vasopressin receptor antagonists for the treatment of heart failure: a systematic review and meta-analysis of randomized controlled trials.New Targets in the Drug Treatment of Heart Failure.Electrolyte disorders with platinum-based chemotherapy: mechanisms, manifestations and management.Clinical Issues and Controversies in Heart Failure and Transplantation.Diuretic usage for protection against end-organ damage in liver cirrhosis and heart failure.Pharmacologic Approaches to Electrolyte Abnormalities in Heart Failure.Predictability of tricuspid annular plane systolic excursion for the effectiveness of tolvaptan in patients with heart failure.
P2860
Q24187853-2B594476-6D3E-4188-A435-2973C1406A07Q24201476-4B7C0F83-BA25-4C3D-AAF3-60CF3030DCC0Q26771172-7CF8806B-A5ED-4766-84F7-7C2EEB0CA680Q27027817-7056A774-BC1C-4573-8261-9A3DB1D24408Q33973976-50FE6CFF-5A1C-486E-8B53-E514EDC25207Q34305164-F50834E5-FE1E-40F4-AB15-B556FFC6F710Q34340391-A0A5ED6C-1868-4385-BC0D-8A625436A961Q34570220-761EDA08-79B2-479B-A400-C5D99604CEE2Q34643664-B2F11990-6B1D-4847-9688-4C65F17BB1D3Q34674591-5A971068-EF6E-4F4B-AC20-B91159907FBDQ35026759-85B5D20A-32D4-4799-82F9-B63B034257EEQ35566683-FF3F7C46-6274-4A39-9F5F-EE9990D60D4BQ35690887-62B8D072-0B7E-4A6A-B3CF-238D83FBEE6DQ36131781-84CBF4BE-CBA4-4752-AF61-6F7BEC742300Q36376174-B1E265C2-5E90-4AAE-972A-78095A18FCCFQ36458380-10D067E3-68BC-441E-B7C1-6087CAFA069FQ36964715-03219006-4B84-4F5A-8960-27D2E457C390Q37176415-C2FA63BE-7DE6-4348-B1E6-CF240A4D9B9CQ37383136-14B908DD-3D4E-4A65-BBB0-EDE3E8638CF7Q37385135-AE60EDE5-1D93-4A46-91AF-CE2FC60745F3Q37617559-93F6B180-D6BC-4E12-9922-8198AA4F9C84Q37693937-7F973A67-54B6-47F2-8B75-9811DF79604BQ37765875-5B86E830-35A7-4914-AA62-79C0D81C32C5Q37770574-61008520-9B75-4473-923C-594FC5979BAFQ37783956-607D2247-5695-4C0E-BB72-1B2C4527A18AQ37806693-7DE354CA-5F50-4378-8300-FFCAF9902F32Q37852720-20522356-4931-4853-B926-40F2AFEC756CQ37871412-0D05B756-51B2-40EF-A580-D356F2B8DAA4Q37892906-BC6A8E29-FB96-4591-9B17-0AA7A9933974Q37959051-50819F51-062C-4FC1-98EC-51ED209BB476Q37995861-C49F07B7-7388-4C71-B069-888B4993E8D2Q38160378-FC82654D-A102-4EAF-A7D4-86883FE670E1Q38168120-6E05CD13-5818-436E-815F-04AF2A16FCEFQ38256581-2FB38202-3815-4280-BCDA-D7BF6415C1D8Q38667210-BB1B08AF-C218-4FB8-BE34-4727CBD4371BQ38668802-F5A82406-E297-4C44-AB85-1B3B828638D2Q38682429-9796769D-B569-4D51-97A3-E74054012828Q38779628-8A41463F-92CA-4A93-A3E0-F6054F47310FQ38859478-8E6623D7-1F96-4DC0-A8DD-9EFD6B76EC9EQ38962878-82E9D588-227A-4AD4-9ADA-2F1912F4A3E9
P2860
Vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 27 September 2005
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Vasopressin-2-receptor antagon ...... cretion in human heart failure
@en
Vasopressin-2-receptor antagon ...... retion in human heart failure.
@nl
type
label
Vasopressin-2-receptor antagon ...... cretion in human heart failure
@en
Vasopressin-2-receptor antagon ...... retion in human heart failure.
@nl
prefLabel
Vasopressin-2-receptor antagon ...... cretion in human heart failure
@en
Vasopressin-2-receptor antagon ...... retion in human heart failure.
@nl
P2093
P2860
P921
P1476
Vasopressin-2-receptor antagon ...... cretion in human heart failure
@en
P2093
Cesare Orlandi
Christopher A Zimmer
Guido Boerrigter
John C Burnett
John Ouyang
Lisa C Costello-Boerrigter
William B Smith
P2860
P304
P356
10.1152/AJPRENAL.00195.2005
P577
2005-09-27T00:00:00Z